Alzheimer's Drugs Market, 2012-2017

Published by: Banyan Wharf Consultants Ltd.

Published: Oct. 8, 2012 - 117 Pages


Table of Contents

1 EXECUTIVE SUMMARY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Chapter Outlines
1.4 Key Highlights
1.4.1. Incidence and Prevalence
1.4.2. Acetylcholinesterase (AChE) Inhibitors Dominate the Market
1.4.3. Aricept was the Top Selling Brand; Namenda is Catching Up Fast
1.4.4. Generics are Rapidly Replacing the Established Brands, Especially in the US
1.4.5. The US was the Largest Market for Alzheimer’s Drugs in 2011
1.4.6. Several New Drugs are in the Pipeline
1.4.7. Opportunities in the Market Outpace the Threats
2 INTRODUCTION
2.1. Dementia and Alzheimer’s
2.2. Cause
2.3. Incidence and Prevalence
2.4. High Burden of Dementia
2.5. Poor Diagnosis Rates
2.6. Risk Factors
2.7. Stages of Alzheimer’s Disease
2.8. Treatment of Alzheimer’s Disease
3 ALZHEIMER’S DRUGS MARKET, 2011-2017
3.1. Chapter Overview
3.2. State of Alzheimer’s Drugs Market in 2011
3.2.1. Acetylcholinesterase (AChE) Inhibitors Continued to Dominate the Market
3.2.1.1. Comparison of AChE Inhibitors and NMDA Receptor Antagonists
3.2.2. Four Leading Drugs Captured 87% of the Market in 2011
3.2.3. With Sales of Aricept, Eisai Captured More Than 33% of the Market
3.3. Alzheimer’s Treatment Market Forecast, 2011-2017
4 ACETYLCHOLINESTERASE (AChE) INHIBITORS MARKET, 2011-2017
4.1. Overview
4.2. AChE Inhibitors Market in 2011
4.2.1. Leading Segments in the AChE Inhibitors Market
4.2.2. Aricept Captured 61.2% of the AChE Inhibitors Market in 2011
4.3. Aricept (Eisai/Pfizer), 2011-2017
4.3.1. Aricept Sales in 2011
4.3.1.1. Launch of Generics in the Market
4.3.1.2. Aricept Sales Declined By More Than 90% in the US
4.3.1.3. Strong Growth in Japan Despite the Competition From Aricept Generics and Other Branded Drugs
4.3.2. Life Cycle Management (LCM): Exploring Additional Dosage and Formulations
4.3.2.1. LCM Activities in the US
4.3.2.2. LCM Activities in Japan
4.3.3. Aricept Sales Forecast, 2012-2017
4.3.3.1. Impending Patent Expiries, 2012-2013
4.3.3.2. Marketing Efforts for Aricept
4.3.4. Aricept in Summary
4.4. Exelon/ Exelon Patch (Novartis), 2011-2017
4.4.1. Exelon Sales in 2011
4.4.1.1. Exelon Patch Contributed More Than 75% Of The Sales in 2011
4.4.1.2. Europe was the Largest Market for Exelon in 2011
4.4.2. Launch of Generics in the Market
4.4.3. Rivastigmine Patch Launched in Japan
4.4.4. Exelon Sales Forecast, 2012-2017
4.4.5. Exelon in Summary
4.5. Razadyne / Reminyl (Janssen / Shire), 2011-2017
4.5.1. Razadyne / Reminyl Sales in 2011
4.5.2. Launch of Generics in the Market
4.5.3. Razadyne / Reminyl in Summary
4.6. AChE Inhibitors Market, 2011-2017
5 NMDA RECEPTOR ANTAGONISTS MARKET, 2011-2017
5.1. Overview
5.2. Mechanism of Action
5.3. NMDA Receptor Antagonist Market in 2011
5.3.1. Leading Drugs in the NMDA Receptor Antagonist Market
5.4. Namenda (Forest Laboratories), 2011-2017
5.4.1. ‘Pay to Delay’ Deal for Namenda
5.4.2. Expectations from Namenda XR to Save Sales Erosion
5.4.3. Namenda Sales Forecast, 2012-2017
5.4.4. Namenda in Summary
5.5. Ebixa / Abixa (H.Lundbeck)
5.5.1. Ebixa Sales Represented 17% of Lundbeck’s Revenue in 2011
5.5.2. Ebixa Sales Forecast, 2011-2017
5.6. Axura / Akatinol (Merz)
5.6.1. Axura Sales Forecast, 2012-2017
5.7. Memary (Daiichi Sankyo)
5.7.1. Memary Sales Forecast, 2012-2017
5.8. NMDA Receptor Antagonist Market, 2012-2017
6 REGIONAL MARKETS FOR ALZHEIMER’S DRUGS 2011
6.1. Overview
6.2. The US was the Largest Market for Alzheimer’s Drugs in 2011
6.3. The US Market for Alzheimer’s Treatment, 2011-2017
6.3.1. Leading Drugs in the US Alzheimer’s Treatment Market, 2011
6.3.1.1. 61.7% of the Market was Captured by Namenda, a Comparatively Newer Drug
6.3.2. Facts About Alzheimer’s in the US
6.3.3. Steps to Combat Alzheimer’s: Regulatory and National Initiatives
6.3.4. The US Alzheimer’s Treatment Market Forecast, 2012-2017
6.4. The European Market for Alzheimer’s Treatment, 2011-2017
6.4.1. Leading Drugs in the European Alzheimer’s Treatment Market, 2011
6.4.2. GERMANY
6.4.2.1. Availability and Reimbursement of Anti-Dementia Drugs
6.4.2.2. National Plan and Initiatives Of Regulatory Authorities
6.4.3. FRANCE
6.4.3.1. Availability and Reimbursement of Anti-Dementia Drugs
6.4.3.2. National Alzheimer’s Plan
6.4.4. THE UK
6.4.4.1. Availability and Reimbursement of Anti-Dementia Drugs
6.4.4.2. Burden of Dementia in the UK
6.4.4.3. National Dementia Plan
6.4.5. SPAIN
6.4.5.1. Availability and Reimbursement of Anti-Dementia Drugs
6.4.6. ITALY
6.4.6.1. Availability and Reimbursement of Anti-Dementia Drugs
6.4.7. European Alzheimer’s Treatment Market Forecast, 2012-2017
6.5. The Japanese Market for Alzheimer’s Treatment, 2011-2017
6.5.1. Leading Drugs in the Japanese Alzheimer’s Treatment Market, 2011
6.5.1.1. Aricept: The Ageing Ruler of the Japanese Alzheimer’s Market
6.5.1.2. Memary or Exelon: The Successor to Aricept?
6.5.1.3. Other New Introductions to the Japanese Market
6.5.2. Initiatives to Combat Alzheimer’s
6.5.3. Japanese Alzheimer’s Treatment Market, 2012-2017
6.5.3.1. Threat to Aricept
6.5.3.2. Downward Repricing of Aricept and Reminyl
6.6. Summary of Regional Distribution of Alzheimer’s Treatment Market, 2011-2017
7 ALZHEIMER’S DRUGS IN THE PIPELINE 2012
7.1. Drugs in Phase I and Phase II
7.2. Drugs in Phase III: Hype or Hope?
7.2.1. Monoclonal Antibodies Targeting ß-amyloid
7.2.1.1. Bapineuzumab (Janssen / Pfizer & Elan / Wyeth)
7.2.1.2. Solanezumab (Eli Lilly)
7.2.2. Intravenous Immunoglobulin Targeting ß-amyloid
7.2.2.1. Gammagard (IGIV) (Baxter Healthcare)
7.2.3. Huperzine A (Shandong Luye Pharmaceutical Company)
7.2.4. Docosahexaenoic Acid (Martek Biosciences)
8 PROFILES OF LEADING COMPANIES
8.1. EISAI
8.1.1. Geographical Presence
8.1.2. Financial Performance
8.1.3. Marketed and Pipeline Drugs
8.1.4. Recent Developments
8.2. PFIZER
8.2.1. Geographical Presence
8.2.2. Financial Performance
8.2.3. Marketed and Pipeline Drugs
8.2.4. Recent Developments
8.3. FOREST LABORATORIES
8.3.1. Geographical Presence
8.3.2. Financial Performance
8.3.3. Marketed and Pipeline Drugs
8.4. H. LUNDBECK
8.4.1. Geographical Presence
8.4.2. Financial Performance
8.4.3. Marketed and Pipeline Drugs
8.5. NOVARTIS
8.5.1. Geographical Presence
8.5.2. Financial Performance
8.5.3. Marketed and Pipeline Drugs
9 SWOT ANALYSIS
9.1. Overview
9.2. Strengths
9.2.1. Alzheimer’s Disease: Silently Growing Child
9.2.2. Ageing Global Population
9.2.3. Unmet Needs in the Market
9.2.4. Alzheimer’s Now a National Concern
9.3. Weaknesses
9.3.1. The Unsolved Mystery
9.3.2. Lack of Awareness
9.3.3. Poor Diagnosis Rates
9.3.4. Side Effects of Available Drugs
9.3.5. Patent Expiry and Launch of Generics
9.4. Opportunities
9.4.1. Growing Pharmaceutical Markets of Emerging Countries
9.4.2. Diagnostic Tests in Development to Allow Early Diagnosis
9.4.3. The Pipeline is Rich
9.4.4. Unresponsiveness to AChE Inhibitors
9.4.5. Prodromal AD
9.5. Threats
9.5.1. High Rate of Drug Failure
9.5.2. Pricing Pressures
10 CONCLUSIONS
10.1. Alzheimer’s: A Chronic Dilemma
10.2. Current State of the Treatment Market
10.3. Attractiveness of the Pipeline
10.4. Key Driving Factors
10.5. Concluding Remarks

Abstract

Alzheimer’s disease is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. With ageing world population, the number of patients suffering from Alzheimer’s disease is expected to increase in the future. There is a huge unmet need in the market owing to lack of effective, disease-modifying drugs.

Alzheimer’s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patents of leading drugs have either expired or are close to expiry. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity.

The pipeline for Alzheimer’s drugs is rich, with drug developers looking for drugs with disease-modifying ability rather than just symptomatic treatments. However, the recent failure of several Alzheimer’s drugs in late stage clinical trials present the challenges of developing disease-modifying drugs for areas with an unknown cause. The uncertainty related to the cause of disease, along with unexpected side effects of drugs due to differential responses by individual brains, pose major challenges for drug developers.

Amongst other things, this report provides a detailed overview of the most promising pipeline drugs for the treatment of Alzheimer’s. The market is desperate for a therapy that can slow or reverse disease progression. The next five years, from 2012-2017, will see the launch of many new drugs.

Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.